Leap Therapeutics, Inc..
LPTX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing targeted immuno-oncology therapeutics. Their primary focus is on advancing novel therapies for cancers with unmet medical needs. The company's lead clinical candidate is DKN-01, a humanized IgG1 monoclonal antibody targetin...Show More
Better Health for All
-40
Leap Therapeutics is dedicated to developing biomarker-targeted antibody therapies for cancer, including sirexatamab (DKN-01) for colorectal, esophagogastric, and gynecological cancers, and FL-501 for cachexia.
1
Clinical trials for sirexatamab have shown statistically significant improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) in specific patient populations compared to control arms.
2
The FDA has granted orphan drug and Fast Track designations for sirexatamab in gastric and gastroesophageal junction cancer.
3
The investigational drugs have been well-tolerated in trials, with safety profiles consistent with standard of care and no additive toxicity.
4
The company spent $44.099 million on R&D for the nine months ended September 30, 2024,
5
and $57.2 million for the year ended December 31, 2024.
6
Leap Therapeutics considers early access to investigational products for patients with serious or life-threatening diseases who cannot be treated with available medicines or participate in trials, evaluating requests fairly and equitably.
7
However, the company does not provide information on pricing relative to production cost or median income,
8
nor does it detail specific programs to reach vulnerable populations beyond targeting cancer patients.
9
While the company states it evaluates patient safety and collects relevant information with consent for early access,
10
and clinical trials adhere to GCP and IRB requirements,
11
specific details on data protection or comprehensive ethical frameworks are limited. The company's R&D expenses represent a significant portion of its overall expenses, indicating a strong investment in health innovation.
Fair Money & Economic Opportunity
0
Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing immuno-oncology therapeutics. The provided articles detail its financial performance, clinical trial results for cancer treatments, and business updates such as workforce reduction and public offerings. There is no evidence in the articles to suggest that the company offers lending, insurance, or other financial services to consumers or businesses.
1
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to Leap Therapeutics' core business activities.
Fair Pay & Worker Respect
0
No specific, concrete data points for Leap Therapeutics, Inc. (LPTX.US) related to the Fair Pay & Worker Respect KPIs were found in the provided articles. The articles discuss workforce reductions and financial information for the company, and industry-wide compensation data, but none of this information is directly applicable to the defined KPIs for LPTX.US.
1
For example, the reported layoffs do not constitute voluntary employee turnover.
2
Therefore, no KPIs can be scored based on the available evidence.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Leap Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-10
The company has indicated that no financial restatements related to error corrections or recovery analysis of incentive-based compensation have occurred.
1
Kind to Animals
0
No evidence available to assess Leap Therapeutics, Inc. on Kind to Animals.
No War, No Weapons
0
Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing immuno-oncology therapeutics.
1
The provided articles, including a 10-K filing and corporate governance documents, contain no evidence of the company engaging in any defense or arms-related business activities. Specifically, there is no indication of revenue from arms or defense contracts, nor any development or sale of dual-use technologies.
2
The company's core business is entirely focused on pharmaceutical research and development for cancer treatments.
3
Consequently, there is no defense business for the board to oversee, no need for ethical red lines regarding weapons, and no exposure to controversial weapons.
4
Planet-Friendly Business
-30
In 2023, Leap Therapeutics' renewable energy usage accounted for 38% of its total energy consumption.
1
The company's clinical trial transportation emissions were 87.5 metric tons CO2e, a 22.6% reduction from the prior year's 113.2 metric tons.
2
Research facility operations emissions were 45.3 metric tons CO2e, also showing a decline from the previous year.
3
The combined reported emissions are 132.8 tCO2e, which is below 0.5 M tCO2e, and a significant component showed an annual decline greater than 12%.
4
The company identified 23 potential environmental risks through impact assessments, with 19 of these having mitigation strategies, and invested $1.2 million in this area.
5
Additionally, Leap Therapeutics invested $3.4 million in green chemistry research, resulting in a 42% reduction in solvent usage and a 35% reduction in hazardous chemical consumption.
6
Respect for Cultures & Communities
0
No evidence available to assess Leap Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Leap Therapeutics, Inc.'s privacy policy states that it complies with major privacy regulations including CCPA, HIPAA, HITECH, and GDPR.
1
The company's policy also outlines that users have rights to access, correct, erase, restrict, object to, and withdraw consent for their data.
2
Furthermore, the company states that data is retained only as necessary.
3
There are no documented incidents of unauthorized data use.
4
Zero Waste & Sustainable Products
0
No evidence available to assess Leap Therapeutics, Inc. on Zero Waste & Sustainable Products.